The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives,
processes for their preparation, pharmaceutical compositions comprising said derivatives,
and their use in the prevention and treatment of illness, in particular which is
mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or
senile dementia.